熱門資訊> 正文
BioNTech因Eristobart肺癌晚期中位生存数据而上升
2026-09-14 23:16
- BioNTech (BNTX) is up ~3% in Monday morning trading after posting non-pivotal stage 1 data on median overall survival from a phase 3 trial of gotistobart in squamous non-small cell lung cancer.
- Results from the PRESERVE-003 trial found that patients on gotistobart, after failing on immunotherapy and chemotherapy, almost doubled survival compared with standard-of-care chemo.
- At data cut-off, with a median follow-up of 25.4 months, median overall survival was 18.5 months for patients treated with gotistobart monotherapy compared to 10 months for patients treated with docetaxel.
- Grade ≥3 treatment-related adverse events were reported in 44.4% of patients on gotistobart and 48.8% of patients on docetaxel.
- The pivotal stage 2 portion of PRESERVE-003 is under way.
- Gotistobart is a CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells.
More on BioNTech
- BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
- BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
- BioNTech SE 2026 Q2 - Results - Earnings Call Presentation
- RFK Jr. is probing if U.S. troops died of COVID shots: report
- Arcturus, Moderna fall after BioNTech's cancer vaccine setback
推薦文章
美股前瞻 | 霍爾木茲海峽或7天內重開！國際油價齊挫，三大期指轉升；美聯儲「二把手」今夜發言；阿里雲棲大會加碼AI基建及自研芯片
Meta點燃半導體、CPU「超級行情」！英特爾年內勁升超230%，AI硬件還有哪些標的獲看好？
華盛早報 | 兩大利好引爆芯片股！英特爾大漲12%，AMD市值破萬億美元；Muse智能體助推Meta飆升11%；阿里雲棲大會今日開幕
美股前瞻 | 中美高層會談釋放積極信號！納指期貨升逾1%；比特幣再度站上8.5萬美元；英特爾盤前升逾5%，佈局先進封裝劍指光通信賽道
新股申購 | 四隻新股今起招股！PCB龍頭景旺電子、直驅機器人公司本末科技、羅博特科、彤程新材在列
港股異動 | 創新葯概念集體走高，英派藥業-B飆漲逾27%，榮昌生物、康方生物、信達生物漲逾6%，藥明生物漲逾5%
華盛早報 | 中美經貿磋商正在紐約進行！特朗普引爆資源股！GLND夜盤飆升119%；景旺電子等四隻新股今起招股
港股周報 | 加息落地！科技股企穩反彈，恆生科指漲近2%；利潤率比肩戴爾？聯想周漲20%再創新高
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
